Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios”,Statistics in Biopharmaceutical Research

当前位置： X-MOL 学术 › Stat. Biopharm. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios”
Statistics in Biopharmaceutical Research ( IF 1.8 ) Pub Date : 2020-10-28 , DOI: 10.1080/19466315.2020.1825522
Ray S Lin ₁ , Ji Lin ₂ , Satrajit Roychoudhury ₃ , Keaven M Anderson ₄ , Tianle Hu ₅ , Bo Huang ₆ , Larry F Leon ₇ , Jason J Z Liao ₄ , Rong Liu ₈ , Xiaodong Luo ₉ , Pralay Mukhopadhyay ₁₀ , Rui Qin ₁₁ , Kay Tatsuoka ₁₂ , Xuejing Wang ₁₃ , Yang Wang ₁₄ , Jian Zhu ₁₅ , Tai-Tsang Chen ₁₆ , Renee Iacona ₁₀ ,

Affiliation

Genentech/Roche, South San Francisco, CA.
Sanofi US, Cambridge, MA.
Pfizer Inc., New York, NY.
Merck & Co., Inc., North Wales, PA.
Sarepta Therapeutics, Cambridge, MA.
Pfizer Inc., Groton, CT.
Celgene Co., San Diego, CA.
Celgene Co., Summit, NJ.
Sanofi US, Bridgewater, NJ.
Astra Zeneca, Washington, DC.
Janssen Research & Development, LLC, Raritan, NJ.
Bristol-Myers Squibb, Lawrenceville, NJ.
Eli Lilly and Company, Indianapolis, IN.
Teclison Ltd., Montclair, NJ.
Servier Pharmaceuticals, Boston, MA.
GSK, Collegeville, PA.

(2020). Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios”. Statistics in Biopharmaceutical Research: Vol. 12, No. 4, pp. 520-521.

中文翻译：